Systematic reviewindependent cross-checkabstract checked★ key study I-GRN-101 in-depth review
Most people who think they react to gluten do not react in blinded tests
Suspected Nonceliac Gluten Sensitivity Confirmed in Few Patients After Gluten Challenge in Double-Blind, Placebo-Controlled Trials.
Overview
Molina-Infante J et al.. Clin Gastroenterol Hepatol 2017 · PMID 27523634 · DOI 10.1016/j.cgh.2016.08.007
Only 16% of 231 people with suspected gluten sensitivity reacted specifically to gluten in blinded challenges.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Check if suspected gluten sensitivity is confirmed under blinding.
- How was the study done?
Combined data of 10 blinded placebo-controlled trials.
- How many people, animals or samples were studied?
1312 adults.
- What was actually found?
Gluten-specific symptoms in 38 of 231 (16%); many had placebo reactions.
- How large was the observed effect?
16% confirmed; 40% of these also reacted to placebo.
- What do the results mean in everyday life?
Most self-diagnosed gluten sensitivity is probably not caused by gluten itself.
- What are the study's limitations?
Heterogeneous trials, short report.
- What does it say about Elawady's specific claim?
Partly supports the claim for non-coeliac sensitivity; says nothing against coeliac disease.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
It cannot show that gluten-related disorders do not exist; coeliac disease is a separate, proven disease.
Scientific in-depth review
1. Full reference
- Authors
- Molina-Infante J et al.
- Journal
- Clin Gastroenterol Hepatol
- Year
- 2017
- Identifier
- PMID 27523634 DOI 10.1016/j.cgh.2016.08.007
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract/PubMed record
2. Research question
How often is suspected non-coeliac gluten sensitivity (NCGS) confirmed by a double-blind placebo-controlled gluten challenge?
3. Study design and population
- Study design
- Systematic review – Pooled analysis/systematic overview of 10 double-blind placebo-controlled gluten-challenge trials (short report)
- Population
Adults with suspected NCGS who responded to a gluten-free diet
- Country
Multinational (trials from several countries)
- Period
Trials published up to 2016
- Sample size
10 trials, 1312 adults (231 NCGS patients analysed for gluten-specific response)
- Inclusion and exclusion criteria
Double-blind placebo-controlled gluten-challenge trials in adults without coeliac disease
4. Methods and endpoints
- Exposure / intervention
Gluten challenge 2-52 g/day for 1 day to 6 weeks
- Comparator
Placebo (gluten-free products, xylose, whey, rice or corn starch; some containing fermentable carbohydrates)
- Endpoints
Gluten-specific symptom recurrence; nocebo response
- Statistical methods
Descriptive pooling of proportions (no formal meta-analytic model reported in the abstract)
5. Actual results
- Results
Most studies found gluten challenge increased symptom scores versus placebo; however, only 38 of 231 NCGS patients (16%) showed gluten-specific symptoms; 40% of these had a nocebo response (similar or increased symptoms with placebo).
- Absolute risks
not reported
- Authors' conclusion
Heterogeneity and methodological flaws cast doubt on gluten as the culprit in most patients with presumptive NCGS; nocebo effect is important.
6. Strengths
- Only blinded placebo-controlled challenges
- Directly addresses whether self-reported gluten sensitivity is gluten-specific
7. Weaknesses
- Short report; no formal risk-of-bias or GRADE assessment in abstract
- Very heterogeneous doses, durations and placebos
- Some placebos contained FODMAPs, which may cause symptoms themselves
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Brief overview by two authors; search and selection methods not detailed in the abstract.
9. Assessment of the statistical interpretation
16% is a proportion of patients, not a pooled effect size; it shows gluten-specific reactions exist only in a minority.
10. Relevance to the specific claim
Supports the narrow part of C-GRN-01: most self-reported gluten sensitivity is not confirmed under blinding. Does not concern coeliac disease.
11. Independent contrary findings
Some trials (e.g. Di Sabatino 2015, PMID 25701700) found a gluten effect in a subgroup; biomarker study I-GRN-103.
12. Transferability to Germany and Europe
High; European and Australian trials dominate.
13. Overall methodological judgement
Good-quality synthesis supporting that NCGS is usually not gluten-specific.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Which wheat components (fructans, amylase-trypsin inhibitors) explain symptoms in the minority?
15. Linked fact checks
- 'There is no such thing as gluten sensitivity'; the real problem is only that white flour turns into a glue-like substance. – Studies supporting the claim